[go: up one dir, main page]

MA33060B1 - Formulations galéniques de composés organiques - Google Patents

Formulations galéniques de composés organiques

Info

Publication number
MA33060B1
MA33060B1 MA34114A MA34114A MA33060B1 MA 33060 B1 MA33060 B1 MA 33060B1 MA 34114 A MA34114 A MA 34114A MA 34114 A MA34114 A MA 34114A MA 33060 B1 MA33060 B1 MA 33060B1
Authority
MA
Morocco
Prior art keywords
tablet
central portion
pharmacy
capsules
organic compounds
Prior art date
Application number
MA34114A
Other languages
Arabic (ar)
English (en)
Inventor
Sabine Desset-Brèthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33060B1 publication Critical patent/MA33060B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une forme de dosage unitaire solide pour administration orale sous la forme d'un comprimé, doté d'une partie centrale et d'un enrobage externe. Ladite partie centrale dudit comprimé comprend une quantité thérapeutiquement efficace d'Aliskiren, ou un sel pharmaceutiquement acceptable de celui-ci, et l'enrobage externe se présente sous la forme d'un revêtement de film qui possède des propriétés de masquage de goût et/ou une fonctionnalité de libération contrôlée. De préférence, le comprimé avec partie centrale fait partie d'un système multiparticulaire, et est en particulier un mini-comprimé. La forme de dosage oral solide est particulièrement adaptée à un usage pédiatrique.
MA34114A 2009-01-28 2010-01-27 Formulations galéniques de composés organiques MA33060B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA33060B1 true MA33060B1 (fr) 2012-02-01

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34114A MA33060B1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Country Status (27)

Country Link
US (1) US20110287100A1 (fr)
EP (1) EP2391345B1 (fr)
JP (1) JP2012516299A (fr)
KR (1) KR20110117199A (fr)
CN (1) CN102300558A (fr)
AR (1) AR075179A1 (fr)
AU (1) AU2010209787B2 (fr)
BR (1) BRPI1007452A2 (fr)
CA (1) CA2749531A1 (fr)
CL (1) CL2011001817A1 (fr)
CO (1) CO6400184A2 (fr)
EC (1) ECSP11011289A (fr)
ES (1) ES2525648T3 (fr)
IL (1) IL213918A0 (fr)
MA (1) MA33060B1 (fr)
MX (1) MX2011007779A (fr)
MY (1) MY153852A (fr)
NZ (1) NZ593622A (fr)
PE (1) PE20110943A1 (fr)
PL (1) PL2391345T3 (fr)
PT (1) PT2391345E (fr)
RU (1) RU2535090C2 (fr)
SG (1) SG172226A1 (fr)
TN (1) TN2011000307A1 (fr)
TW (1) TWI468191B (fr)
WO (1) WO2010086312A1 (fr)
ZA (1) ZA201104489B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (fr) * 2011-11-23 2013-05-29 PLS-Design GmbH Composition pharmaceutique pour le traitement des réactions allergiques
WO2017134600A1 (fr) 2016-02-03 2017-08-10 Novartis Ag Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
US12171878B2 (en) 2018-08-10 2024-12-24 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
GB2585412B (en) 2019-02-22 2023-10-04 Catalent Uk Swindon Zydis Ltd Minimizing aeration of suspensions during in-line mixing
MX2021009844A (es) 2019-02-22 2021-09-10 Catalent Uk Swindon Zydis Ltd Conservacion de particulas de ingredientes farmaceuticos activos revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspension acuosa.
AU2020223894B2 (en) 2019-02-22 2025-09-18 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising Ibuprofen
JP7543291B2 (ja) 2019-02-22 2024-09-02 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 医薬品の崩壊時間を安定させるための、保管中の薬物粒子コーティング材料の凝集を最小限に抑える
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
BR112023001716A2 (pt) 2020-07-31 2023-04-04 Catalent Uk Swindon Zydis Ltd Composições farmacêuticas compreendendo api revestido
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
TW202523280A (zh) * 2023-11-17 2025-06-16 日商第一三共健康事業股份有限公司 固體製劑
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
US20070224260A1 (en) * 2004-04-15 2007-09-27 Dr. Reddy's Laboratories Limited Dosage Form Having Polymorphic Stability
BRPI0516128A (pt) * 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
PT2205279E (pt) * 2007-09-28 2011-07-11 Novartis Ag Associação farmacêutica de aliscireno e valsartan

Also Published As

Publication number Publication date
AR075179A1 (es) 2011-03-16
EP2391345A1 (fr) 2011-12-07
CA2749531A1 (fr) 2010-08-05
CO6400184A2 (es) 2012-03-15
PT2391345E (pt) 2014-12-03
CN102300558A (zh) 2011-12-28
RU2011135417A (ru) 2013-03-10
NZ593622A (en) 2013-12-20
PL2391345T3 (pl) 2015-03-31
EP2391345B1 (fr) 2014-09-03
JP2012516299A (ja) 2012-07-19
ES2525648T3 (es) 2014-12-26
CL2011001817A1 (es) 2012-01-13
MY153852A (en) 2015-03-31
IL213918A0 (en) 2011-07-31
HK1161125A1 (en) 2012-08-24
TN2011000307A1 (en) 2012-12-17
ECSP11011289A (es) 2011-09-30
TW201038300A (en) 2010-11-01
WO2010086312A1 (fr) 2010-08-05
TWI468191B (zh) 2015-01-11
RU2535090C2 (ru) 2014-12-10
KR20110117199A (ko) 2011-10-26
ZA201104489B (en) 2012-02-29
BRPI1007452A2 (pt) 2016-02-16
SG172226A1 (en) 2011-07-28
AU2010209787A1 (en) 2011-07-14
PE20110943A1 (es) 2012-01-22
MX2011007779A (es) 2011-08-12
AU2010209787B2 (en) 2013-06-06
US20110287100A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
MA33060B1 (fr) Formulations galéniques de composés organiques
MA54411B1 (fr) Compositions contenant de l'ibrutinib
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA30807B1 (fr) Compositions pharmaceutiques.
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MY156822A (en) Indole derivatives as s1p1 receptor agonists
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA33299B1 (fr) Nouvelle formulation de naproxène
CY1110824T1 (el) Διασπεipoμενη στο στομα φαρμακευτικη συνθεση για απο του στοματος, μεσω του στοματικου βλεννογονου ή υπογλωσσια χορηγηση αγομελατινης
WO2007095091A3 (fr) Administration orale d'agents thérapeutiques utilisant des agonistes à jonctions serrées
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MA31706B1 (fr) Formulations galéniques de composés organiques
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
BR112012016460A2 (pt) diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica.
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
EP4233850A3 (fr) Formulations de capsules
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MA29722B1 (fr) Schema posologique pour le prasugrel